Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A
Go back to Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (A| Beam Inc. (NASDAQ: BEAM) | Delayed: 29.03 -0.38 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.41 | 52 Week High | $83.60 | |||
| Open | $29.46 | 52 Week Low | $82.96 | |||
| Day High | $30.50 | P/E | 12.96 | |||
| Day Low | $28.67 | EPS | $2.24 | |||
| Volume | 1,588,226 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 29.03 -0.38 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.41 | 52 Week High | $83.60 | |||
| Open | $29.46 | 52 Week Low | $82.96 | |||
| Day High | $30.50 | P/E | 12.96 | |||
| Day Low | $28.67 | EPS | $2.24 | |||
| Volume | 1,588,226 | |||||
